氟伐他汀对代谢综合征患者骨密度的影响

Effects of fluvastatin on bone mineral density in patients with metabolic syndrome

目的探讨氟伐他汀对代谢综合征患者骨密度的影响。方法63例代谢综合征患者随机分为氟伐他汀组(n=32)及对照组(n=31),两组病例均予治疗性生活方式转变(therapeutic lifestyle changes,TLC)干预。治疗前及治疗36周后分别检测腰椎骨密度(BMD-LS)、股骨颈骨密度(BMD-Fn)、股骨近端骨密度(BMD-Ftot)及血脂谱。结果氟伐他汀组在治疗后36周BMD-LS、BMD-Fn、BMD-Ftot分别升高了3.1%、1.3%、1.0%,对照组分别下降了1.8%、1.6%、1.4%,两组各参数比较差异有显著性意义(P<0.05);氟伐他汀组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)分别降低了25.7%、37.9%、23.4%,高密度脂蛋白胆固醇(HDL)升高了8.0%,与对照组比较差异有显著性意义(P<0.05)。结论氟伐他汀能提高代谢综合征患者的骨密度。

Objective To evaluate the effect of flurvastatin on bone density in patients with metabolic syndrome. Methotis Sixty-three patients with metabolic syndrome were randomly divided to fluvastatin-treated group （ n = 32） and control group （ n = 31 ）. The bone mineral density at the lumbar spine （ BMD-LS）, femoral neck （BMD-Fn） and the proximal end of the femur （BMD-Ftot） was measured by dual energy X-ray densitometry before and after 36 weeks of treatment between both groups. The blood samples were collected for determination of lipid profile. Results Therewere a significant increase of BMD-LS, BMD-Fn and BMD-Ftot in fluvastatin-treated group than in control group （ P 〈 0. 05 ）. The lipid-lowering effect of fluvastatin was confirmed with a decrease of 25.7 %, 37.9 %, 23.4 %, and an increase of 8.0 % in serum total cholesterol, low density lipoprotein-cholesterol, triglyceride, and high density lipoprotein-cholesterol respectively. Conclusion Fluvastatin is favorable to the increase of bone mineral density in patients with metabolic syndrome.